alpha-lipoic acid
Small molecule targets EGFR, TNF via inhibition
Trials 65 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05371288 | Jun → Sep 2025 | COVID-19 | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 0 | NCT05945160 | Jan → Aug 2024 | vestibular disorder | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT06242535 | Jul 2023 → May 2024 | cognitive disorder, depressive disorder, hyperlipidemia, hypertensive disorder +1 | Hoskinson Health and Wellness Clinic | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT04042935 | Feb 2020 → Feb 2021 | head and neck squamous cell carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT03493841 | Jun 2018 → Jan 2019 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Rebecca Spain | Completed | No outcome recorded |
| Phase 1 | NCT02348125 | Mar 2016 → Jun 2017 | autism spectrum disorder, mitochondrial disease | Drexel University | Unknown | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1 | NCT00117403 | Jan 2006 → Sep 2007 | Alzheimer disease | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1/28 trials · 1 missed | ||||||
| Phase 1/2 | NCT05083546 | Dec 2024 → Dec 2025 | obesity disorder | University of California, San Francisco | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02696512 | Mar 2016 → Mar 2017 | brain injury | International Brain Research Foundation | Unknown | No outcome recorded |
| Phase 1/2 | NCT02613572 | Nov 2015 → Feb 2019 | age-related macular degeneration | University of Pennsylvania | Completed | Missed primary |
| Phase 1/2 | NCT01780974 | Apr 2013 → Oct 2015 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 1/2 | NCT01313117 | Feb 2012 → Aug 2013 | peripheral neuropathy | Northwestern University | Completed | No outcome recorded |
| Phase 1/2 | NCT01537549 | Sep 2010 → Sep 2013 | progressive supranuclear palsy | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 1/2 | NCT00079807 | Sep 2003 → Feb 2007 | HIV infectious disease, peripheral neuropathy | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 1/2 | NCT00010842 | Sep 1999 → Dec 2004 | multiple sclerosis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT05713799 | Oct 2026 → Mar 2030 expected | obesity disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07564479 | Mar 2026 → Mar 2027 expected | cisplatin toxicity | Minia University | Recruiting | No outcome recorded |
| Phase 2 | NCT07182526 | Sep 2025 → May 2026 overdue | polycystic ovary syndrome | Al-Mustansiriyah University | Recruiting | No outcome recorded |
| Phase 2 | NCT06568185 | May → Oct 2024 overdue | diabetic polyneuropathy | Universiti Sains Malaysia | Recruiting | No outcome recorded |
| Phase 2 | NCT06703593 | Oct 2023 → Apr 2025 | female breast carcinoma | British University In Egypt | Completed | No outcome recorded |
| Phase 2 | NCT02910531 | Jun 2017 → Dec 2024 | cystinuria | Thomas Chi, MD | Completed | No outcome recorded |
| Phase 2 | NCT02382328 | Feb → Jun 2016 | carpal tunnel syndrome | Hospital Civil de Guadalajara | Completed | No outcome recorded |
| Phase 2 | NCT02171104 | Jul 2014 → Jan 2026 overdue | Hurler syndrome, Krabbe disease, Niemann-Pick disease type B, Niemann-Pick disease, type C2 +15 | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01398423 | Jun 2011 → Jul 2012 | hypertensive disorder, type 2 diabetes mellitus | InVasc Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01054768 | Aug 2009 → Apr 2013 | sickle cell disease | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 2 | NCT00490867 | Jul 2004 → Aug 2007 | type 2 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT00033176 | Feb 2002 → Aug 2004 | AIDS | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06650384 | Nov 2024 → Jan 2026 | poisoning | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT06940557 | Dec 2023 → Sep 2024 | carpal tunnel syndrome | Universiti Putra Malaysia | Completed | No outcome recorded |
| Phase 2/3 | NCT05808946 | Mar 2023 → Oct 2024 | infectious disease with sepsis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05009901 | Jun 2022 → Aug 2023 | obstructive sleep apnea syndrome | University of British Columbia | Unknown | No outcome recorded |
| Phase 2/3 | NCT03788759 | Sep 2019 → Dec 2021 | disorder of defective peroxisome oxidative status, schizophrenia | Drug Research and Development Center, Federal University of Ceara | Completed | No outcome recorded |
| Phase 2/3 | NCT00477607 | Oct 2007 → Mar 2011 | cancer of unknown primary site, platinum-induced ototoxicity | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07630779 | Mar → Sep 2026 overdue | polycystic ovary syndrome | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 3 | NCT06286098 | Feb 2025 → Nov 2027 expected | kidney disorder | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06418347 | Apr 2024 → Aug 2025 | female infertility, polycystic ovary syndrome | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT01888861 | Feb → Sep 2013 | disorder of defective peroxisome oxidative status, nutritional disorder | najmeh hejazi | Unknown | No outcome recorded |
| Phase 3 | NCT01261143 | Aug 2010 → Apr 2012 | diabetic neuropathy | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00112996 | Jan 2007 → Apr 2014 | cancer of unknown primary site, childhood malignant neoplasm, poisoning | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 415 trials · 1 met primary | ||||||
| Phase 4 | NCT06406127 | Apr 2024 → Apr 2025 | breast cancer, nervous system disorder | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT06040190 | Nov 2023 → Jul 2026 overdue | burning mouth syndrome | Federal University of Minas Gerais | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05813496 | Oct 2022 → Aug 2024 | diabetic polyneuropathy | Eva Pharma | Completed | No outcome recorded |
| Phase 4 | NCT05211622 | Mar → Dec 2022 | stomatitis | University of Palermo | Unknown | No outcome recorded |
| Phase 4 | NCT04846673 | May 2021 → Nov 2022 | diabetic polyneuropathy | Yuhan Corporation | Completed | Met primary |
| Phase 4 | NCT04475276 | Feb 2021 → Dec 2023 | NAFLD1 | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT04064814 | Sep 2019 → Apr 2021 | migraine disorder | All India Institute of Medical Sciences, Bhubaneswar | Completed | No outcome recorded |
| Phase 4 | NCT03491969 | Jan 2019 → Feb 2025 | heart failure | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03023514 | Mar 2015 → Jun 2016 | female infertility | Lo.Li.Pharma s.r.l | Completed | No outcome recorded |
| Phase 4 | NCT01978405 | Nov 2013 → Jun 2014 | acute kidney injury | Xiang Guang-da | Unknown | No outcome recorded |
| Phase 4 | NCT01877590 | Nov 2013 → Jul 2015 | coronary artery disorder, type 2 diabetes mellitus | Wuhan General Hospital of Guangzhou Military Command | Completed | No outcome recorded |
| Phase 4 | NCT01524861 | Dec 2011 → Dec 2015 | Tako-tsubo cardiomyopathy, sympathetic nervous system disorder | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT01056497 | Feb 2010 → Jan 2011 | prediabetes syndrome, type 2 diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01406704 | Jan 2004 → Dec 2010 | metabolic dysfunction-associated steatohepatitis | Seoul St. Mary's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02016495 | ? → Feb 2013 | pregnancy disorder | AGUNCO Obstetrics and Gynecology Centre | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT07455890 | Jul 2024 → Jan 2026 | male infertility | Mst.Sumyara Khatun | Completed | No outcome recorded |
| — | NCT07391709 | Feb → Jul 2024 | priapism | Trabzon Kanuni Education and Research Hospital | Completed | No outcome recorded |
| — | NCT06056687 | Mar 2023 → Jan 2024 | cardiomyopathy, type 2 diabetes mellitus | Damanhour University | Completed | No outcome recorded |
| — | NCT05360602 | Jan 2022 → Jul 2023 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT06787781 | Jun 2021 | — | University of Messina | Completed | No outcome recorded |
| — | NCT04322240 | Apr → Oct 2020 | diabetic polyneuropathy, type 2 diabetes mellitus | Benha University | Completed | No outcome recorded |
| — | NCT05729529 | Jan 2020 → May 2023 | burning mouth syndrome | University of Catania | Unknown | No outcome recorded |
| — | NCT02666170 | Jan → Sep 2016 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| — | NCT02651636 | Jun 2014 → Jul 2015 | menstrual disorder, polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT00187564 | Aug 2004 → Oct 2005 | type 1 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
| Comparator or background therapy31 trials | ||||||
| Phase 1 | NCT01258699 Comparator | Aug 2009 → ? | — | Bukwang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT07574684 Comparator | Apr 2026 → Jan 2027 expected | non-small cell lung carcinoma | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06131918 Comparator | Jan → Dec 2023 | diabetic polyneuropathy | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT03257514 Comparator | Jun 2017 → Jan 2018 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02760823 Comparator | May 2016 → Jan 2018 | poisoning | Heba Allah Ali Abd El-Halim Mabrouk | Unknown | No outcome recorded |
| Phase 2 | NCT03428139 Comparator | Aug 2013 → Mar 2017 | radiculopathy | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT01471652 Comparator | Mar 2012 → Feb 2013 | myalgic encephalomeyelitis/chronic fatigue syndrome | Columbia University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01396733 Comparator | Apr 2011 → Dec 2012 | cancer, thyroid gland disorder | Asan Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT00719706 Comparator | Aug 2008 → May 2011 | bipolar depression | Mclean Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00237718 Comparator | Apr 2006 → Sep 2010 | end stage renal failure | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT00308971 Comparator | Mar 2006 → Jul 2007 | chronic kidney disease | Vanderbilt University | Completed | No outcome recorded |
| Phase 2/3 | NCT06201611 Comparator | Nov 2024 → Dec 2025 overdue | diabetic polyneuropathy | St. John's Research Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05023863 Comparator | Sep 2021 → May 2022 | mucositis | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2028 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07668141 Comparator | Jun 2026 → Jan 2027 expected | poisoning | Helwan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07456176 Comparator | Feb → May 2026 overdue | chronic obstructive pulmonary disease | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07399743 Comparator | Feb → Jun 2026 overdue | osteoarthritis, knee | Badr University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07157722 Comparator | Aug → Dec 2025 overdue | beta thalassemia | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05679037 Comparator | Jan 2023 → Oct 2024 | type 1 diabetes mellitus | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05369793 Comparator | Aug 2022 → Oct 2023 | diabetic neuropathy, type 2 diabetes mellitus | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04041167 Comparator | Aug 2018 → Jul 2021 | ischemic stroke | Chonnam National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02714543 Comparator | Nov 2013 → Aug 2015 | oral submucous fibrosis | The Oxford Dental College, Hospital and Research Center, Bangalore, India | Completed | No outcome recorded |
| Phase 4 | NCT06151652 Comparator | Jan 2023 → Mar 2024 | atrial fibrillation | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT05266794 Comparator | Jan → Apr 2019 | end stage renal failure | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02439879 Comparator | Dec 2009 → Dec 2010 | diabetic polyneuropathy | Universidad Popular Autónoma del Estado de Puebla | Completed | No outcome recorded |
| — | NCT07381361 Comparator | Apr 2025 → Jan 2026 overdue | burning mouth syndrome | Lu Jiang | Active not recruiting | No outcome recorded |
| — | NCT06067698 Comparator | Oct 2023 → Apr 2025 | ulcerative colitis | Tanta University | Completed | No outcome recorded |
| — | NCT06195137 Comparator | Dec 2021 → Jun 2023 | burning mouth syndrome | Lu Jiang | Completed | No outcome recorded |
| — | NCT02999958 Comparator | Dec 2016 → May 2018 | — | Vitrolife | Completed | No outcome recorded |
| — | NCT00795262 Comparator | Jul 2008 → Jul 2009 | diabetes mellitus, hypertensive disorder | InVasc Therapeutics, Inc. | Completed | No outcome recorded |
| — | NCT00122447 Comparator | May 2005 → May 2011 | glucose intolerance, prediabetes syndrome | Emory University | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 103 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alpha-lipoic acid | “Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an...” NCT04475276 ↗103“Alpha Lipoic Acid (ALA) is a potent antioxidant and anti-inflammatory agent that scavenges reactive oxygen species, regenerates endogenous antioxidants, and modulates...” NCT07456176 ↗ “Alpha-Lipoic Acid (ALA) is a natural molecule that can make a significant contribution to the success of embryo implantation phase, because it exerts, directly or indirectly,...” NCT03023514 ↗ “Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days...” NCT06151652 ↗ “Alpha-lipoic acid (ALA) is a natural short chain fatty acid containing sulfhydryl groups generated from octanoic acid and cysteine in the mitochondria, and is found in both the...” PMID 35023797 ↗ Jan 2022 “SM Fibro (Alpha lipoic acid 50mg, Beta-carotene 10mg, Elemental copper 1mg, Elemental selenium 75mcg, Lycopene 5mg, Vitamin E 10 IU, Zinc sulphate 27.45mg in form of the...” NCT02714543 ↗ “Each tablet contains 4 active ingredients as follows: Alpha lipoic acid 300mg, Vitamin B12 (methylcobalamin) 500mcg, Vitamin B6 (pyridoxine) 8mg, Vitamin B1 (thiamine) 39mg.” NCT06568185 ↗ “Nutraceuticals like alpha-lipoic acid (ALA) may have potential benefits as prophylactic agents for adolescent migraine, with fewer adverse events than existing medications.” PMID 37563914 ↗ Aug 2023 “Each capsule is a combination of vitamins and natural products: Vitamin B1 (100mg); Vitamin B6 (50mg); Niacin (200mg); Alpha Lipoic Acid (150mg); and Piperine (15mg).” NCT06242535 ↗ “We aimed to evaluate the efficacy and safety of roflumilast compared to alpha-lipoic acid (ALA) in type 2 diabetic patients with diabetic neuropathy.” PMID 41256904 ↗ Nov 2025 “We aimed to evaluate the efficacy and safety of roflumilast compared to alpha-lipoic acid (ALA) in type 2 diabetic patients with diabetic neuropathy.” PMID 41256904 ↗ Nov 2025 |
| Known as | 1,2-dithiolane-3-pentanoic acid | “Alpha-lipoic acid (ALA) is an 8-carbon molecule first isolated from bovine liver in 1950 that can cross the blood-brain barrier. It may also be referred to as...” NCT07391709 ↗1“Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria.” NCT06418347 ↗ |
| Known as | 5-(1,2-dithiolan-3- yl) pentanoic acid | “One potential therapeutic is a thiol-containing compound alpha-lipoic acid (thioctic acid, 5-(1,2-dithiolan-3- yl) pentanoic acid, ALA).” NCT02910531 ↗ |
| Known as | 6,8-thioctic acid | “Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an...” NCT04064814 ↗1“Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an...” NCT04475276 ↗ |
| Known as | ALA | “Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an...” NCT04475276 ↗28“Alpha Lipoic Acid (ALA) is a potent antioxidant and anti-inflammatory agent that scavenges reactive oxygen species, regenerates endogenous antioxidants, and modulates...” NCT07456176 ↗ “Alpha-Lipoic Acid (ALA) is a natural molecule that can make a significant contribution to the success of embryo implantation phase, because it exerts, directly or indirectly,...” NCT03023514 ↗ “Alpha-lipoic acid (ALA) is a natural short chain fatty acid containing sulfhydryl groups generated from octanoic acid and cysteine in the mitochondria, and is found in both the...” PMID 35023797 ↗ Jan 2022 “Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.” NCT00112996 ↗ “Nutraceuticals like alpha-lipoic acid (ALA) may have potential benefits as prophylactic agents for adolescent migraine, with fewer adverse events than existing medications.” PMID 37563914 ↗ Aug 2023 “Purpose: To determine whether treatment of obstructive sleep apnea (OSA) patients with a potent oral antioxidant (alpha lipoic acid, ALA) improves cardiovascular health.” NCT05009901 ↗ “Alpha-lipoic acid (ALA) is a naturally occurring compound, synthesized in the mitochondria, that is currently approved to treat diabetic neuropathic pain.” NCT03788759 ↗ “To determine the safety and tolerability of the combination of mirabegron (MG) at a dose of 50mg/d with alpha-lipoic acid (ALA) at a dose of 2400 mg/d.” NCT05713799 ↗ “We aimed to evaluate the efficacy and safety of roflumilast compared to alpha-lipoic acid (ALA) in type 2 diabetic patients with diabetic neuropathy.” PMID 41256904 ↗ Nov 2025 “The intervention under investigation is the administration of oral Alpha-Lipoic Acid (ALA) as an adjunct to standard cisplatin-based chemotherapy.” NCT07564479 ↗ |
| Known as | Alpha lipoic acid 600 mg oral Tablet, Nutricost pharmacetics | “Alpha lipoic acid 600 mg oral Tablet, Nutricost pharmacetics” NCT07182526 ↗ |
| Known as | alpha-Lipoic acid (ALA) | “alpha-Lipoic acid (ALA)” NCT02999958 ↗ |
| Known as | Thiocacid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01258699 ↗ |
| Known as | Thioctacid | “ALA tab 300 mg BID (Thioctacid) + PT” NCT07399743 ↗1“Alpha Lipoic Acid (Thioctacid)” NCT02760823 ↗ |
| Known as | thioctic acid | “Alpha-lipoic acid (ALA) is an 8-carbon molecule first isolated from bovine liver in 1950 that can cross the blood-brain barrier. It may also be referred to as...” NCT07391709 ↗3“One potential therapeutic is a thiol-containing compound alpha-lipoic acid (thioctic acid, 5-(1,2-dithiolan-3- yl) pentanoic acid, ALA).” NCT02910531 ↗ “Alpha-lipoic acid (ALA) known as thioctic acid "600 mg twice daily "is an organosulfur compound found in the mitochondria” NCT06650384 ↗ “Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria.” NCT06418347 ↗ |
| Known as | thioctic acid acid | “alpha lipoic acid drug (thioctic acid acid)” NCT07668141 ↗1“alpha lipoic acid drug (thioctic acid acid)” NCT03257514 ↗ |
| Known as | thiotacid | “Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days...” NCT06151652 ↗1“alpha lipoic acid drug (thiotacid film coated tablets 600 mg)” NCT03257514 ↗ |
| Known as | Thiotex fort | “Alpha Lipoic acid (ALA) (Thiotex fort®) 600mg once daily with their routine therapy just after the dialysis sessions for 3 months.” NCT05266794 ↗ |
| Known as | α-LA | “the viability of alpha-lipoic acid (α-LA) in ensuring against carbon tetrachloride (CCl4)-actuated liver fibrosis and the mechanism(s) involved in this defensive impact were...” PMID 29233029 ↗ Feb 20171“Alpha-Lipoic Acid(α-LA)” NCT03491969 ↗ |
| Known as | α-lipoic acid | “A previous open-label study with α-lipoic acid (ALA), a potent antioxidant, improved patients' negative and cognitive symptoms and markers of lipid peroxidation.” PMID 36584248 ↗ Jan 20234“To assess the efficacy and safety of α-lipoic acid (ALA) over 20 weeks, we conducted a multicenter randomized withdrawal open-label study” PMID 26345602 ↗ Aug 2015 “Then they took α-lipoic acid (ALA) 3 times a day, after meals, 200 mg each time, for 2 consecutive weeks.” NCT07381361 ↗ “α-lipoic acid - intravenous infusion of 600 mg in 250 ml saline solution over 30 minutes” NCT00490867 ↗ “900 mg/d of α-lipoic acid (E/C/ALA)” PMID 22431837 ↗ Jul 2012 |
| Action | Inhibit | “Alpha -Lipoic acid significantly inhibits production of nitric oxide and TNF-alpha.” NCT04475276 ↗ |
| Modality | Small molecule | “naturally occurring dithiol compound” NCT01056497 ↗ |
| Route | Oral | “daily oral alpha-lipoic acid supplements” NCT00079807 ↗ |
| Target | TNF | “Alpha -Lipoic acid significantly inhibits production of nitric oxide and TNF-alpha.” NCT04475276 ↗ |